DoW Peer Reviewed Cancer, Clinical Trial Award
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The fiscal year 2026 Peer Reviewed Cancer Research Program Clinical Trial Award (HT94252526PRCRPCTA), issued by the Defense Health Agency, supports the rapid implementation of clinical trials ranging from phase 0 to phase III. The program aims to address gaps in cancer prevention, diagnosis, treatment, and survivorship for Service Members, Veterans, and their families. Eligible projects may evaluate new drugs, biologics, devices, or emerging technologies, with a total funding cap of 4.5 million dollars per project over a maximum period of four years. Approximately 45 million dollars is available to fund roughly 10 awards. Applications must include a clinical trial and the integration of patient advocates, while animal studies are strictly prohibited. If an Investigational New Drug or Investigational Device Exemption is required, the regulatory application must be submitted by the application deadline. The selection process is based on the ability to achieve program objectives, with evaluations focusing on ethical considerations, personnel and communication, recruitment and retention plans, and statistical analysis. Applicants must be registered in SAM.gov, eBRAP.org, and Grants.gov. Key deadlines include a pre-application due on June 26, 2026, and a full application deadline of October 5, 2026. Post-award requirements include virtual annual milestone meetings starting after the first year to report progress.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Timeline
Response Deadline
Organization & Contact Information
Full Description
Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations.
Distinctive Features:
• Applications to this award mechanism must include a clinical trial.
• Projects can range from phase 0 to phase III.
• If an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or equivalent, is required, a regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The regulatory application should be specific to the product and indication to be tested in the proposed clinical trial.
• Applications are required to include patient advocates.
• Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Defense → Department Of The Army -- Usamraa
Same awarding agency
